🦊/Investors

Lumira Ventures β€” Full Portfolio

61 tracked investments Β· listed companies and verified rows first

Edesa Biotechedesabiotech.cominNASDAQ: EDSA

Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases.

BiotechHealthtechMarkham, US

Pardeep Nijhawan(Executive Officer, Director)Stephen Lemieux(Executive Officer)inMichael Brooks(Executive Officer)Mary Catherine Brisson(Executive Officer)Mark A. McPartland(Executive Officer)Kathi Niffenegger(Executive Officer)in

Co-investorsVenture Ontario

X4 Pharmax4pharma.comin𝕏NASDAQ: XFOR

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in

Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)Partners ResoluteThynk CapitalOmega FundsPolaris Partners

Zymeworkszymeworks.comin𝕏NASDAQ: ZYME

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.

BiotechHealthtechVancouver, US

ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in

Co-investorsBrace PharmaCTI Life Sciences Fund L.P.Nextech InvestWUTIF CapitalAmplitude Venture Capital

Cadence Neurosciencecadenceneuro.cominFeb 2023 Β· $26Mβœ“ verified

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.

BiotechDigital HealthHealthtechMedical DevicesSammamish, US

Kent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)

Board seatGerry BrunkΒ· per SEC Form D

Co-investorsJAZZ Venture PartnersAngelini VenturesF-Prime CapitalIaso Ventures

Spectrawavespectrawave.comin𝕏Sep 2024βœ“ verified

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in

Board seatGerry BrunkΒ· per SEC Form D

Co-investorsS3 VenturesSV Health InvestorsDeerfield Management CompanyJohnson & Johnson Innovation – JJDC

Biotheryxbiotheryx.cominβœ“ verified

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.

BiotechDeep TechMedical DevicesSan Diego, US

Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))inRaymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in

Co-investorsRevelation PartnersSR One Capital Management

Cour Pharmacourpharma.cominπ•βœ“ verified

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsAlpha Wave GlobalRoche Venture FundAngelini VenturesJDRF T1D Fund

Cyrano Therateuticscyranotherapeutics.cominβœ“ verified

Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste.

BiotechDigital HealthHealthtechMedical DevicesDelray Beach, US

Rick Geoffrion(Founder, President and CEO & Board Member)in

Co-investorsRemiges Ventures, Inc.DeepWork Capital

Lqttrxlqttrx.cominπ•βœ“ verified

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinAmy Sehnertin

Co-investorsAmzak HealthadMare BioInnovationsAlexandriaCTI Life Sciences Fund L.P.

Puzzle Medicalpuzzlemed.cominApr 2025 Β· $43Mβœ“ verified

Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.

HardwareHealthtechMedical DevicesMontreal

Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFranΓ§ois Trudeau(Co-founder & CTO, Board Director)inPhilippe GΓ©nΓ©reux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)inMaxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)inYves-Antoine CrΓͺte(Co-founder (Phase 2) & VP Technical R&D and Operations)inGabriel Georges(Co-founder & Clinical Advisor)in

Co-investorsBroadview VenturesAjax HealthDesjardins CapitalBoreal VenturesCathexis VenturesFront Row Ventures+1 more

Thryvtrxthryvtrx.cominπ•βœ“ verified

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

BiotechDigital HealthMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra Odink(President & Chief Development Officer)inAmy Sehnert(Chief Medical Officer)inMatt Killeen(Chief Business Officer)in

BoardSaumya Das(Chief Scientific Advisor)

Co-investorsadMare BioInnovationsAmzak HealthCTI Life Sciences Fund L.P.Fonds de solidaritΓ© FTQ

Xylocorxylocor.comβœ“ verified

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.

BiotechHealthtechMedical DevicesMalvern, US

Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)

BoardGlenn Batchelder(Director)inJames Cohen(Director)

Co-investorsFountain Healthcare PartnersJeito CapitalLongwood FundSofinnova Ventures

Cyrano TherapeuticsinNov 2020 Β· $9M

Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.

HealthtechWashington, US

Richard Geoffrion(Executive Officer, Director)Robert Henkin(Director)

BoardTakahide Koda(Director)

Board seatGerry BrunkΒ· per SEC Form D

Co-investorsRemiges Ventures, Inc.DeepWork Capital

Endotronixendotronix.comin𝕏Jul 2016

Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.

Digital HealthHealthtechMedical DevicesWoodridge, US

Harry Rowland(Executive Officer, Director)inAnthony I Nunez(Executive Officer, Director)inAnthony A. Nunez(Executive Officer, Director)inAnthony Nunez(Founder)in

BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)

Board seatGerry BrunkΒ· per SEC Form D

Co-investorsBioventures InvestorsJumpstart VenturesOSF VenturesSeroba Life SciencesSV Health InvestorsLSP (Life Sciences Partners)

Engage Therapeuticsengagetherapeutics.comin𝕏Sep 2017

Company whose formation and launch the LifeSci team supported.

BiotechHealthtechSummit, US

Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)inOrrin Devinsky(Director)

Board seatGerry BrunkΒ· per SEC Form D

Co-investorsLifeSci Venture Partners

Exact Imagingexactimaging.comin𝕏Feb 2019

Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.

HardwareHealthtechMedical DevicesMarkham, CA

Harold Wodlinger(Director)inRandy AuCoin(President & CEO)inRob Sandler(Executive Officer)inJerrold Wen(Executive Officer)in

BoardWilliam Wortman(Director)Gaston Matthyssens(Director)

Board seatPeter van der VeldenΒ· per SEC Form D

Co-investorsiGan PartnersPMVVenture OntarioVesalius Biocapital Partners

HistoSonicshistosonics.comin𝕏Apr 2019

HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.

BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB

Thomas Davison(Executive Officer, Director)inM. Christine Gibbons(Executive Officer, Director)inWen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)

Board seatGerry BrunkΒ· per SEC Form D

Co-investorsAlpha Wave GlobalAmzak HealthEarly Stage Partners, LPHealthQuest CapitalMichigan Capital NetworkBezos Expeditions+2 more

Pic Therapeuticspictherapeutics.comOct 2022SEC filingmedium confidence

BiotechBoston, US

Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)in

Board seatGerry BrunkΒ· per SEC Form D Β· $35M raise Β· filed Oct 2022

Co-investorsAdvent Life SciencesOrbiMed

Alpha-9 Oncologya9oncology.cominOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FranΓ§ois BΓ©nard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalNextech Invest+8 more

Alveolusbioalveolusbio.comin

Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD.

BiotechHealthtech

C Vivek Lal(Founder & CSO)inAmit Gaggar(Chief Medical Officer)inGaurav Mehta(CEO)in

Amacatheraamacathera.cain

AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells.

BiotechDigital HealthMedical DevicesToronto, CA

Mike Cooke(Co-Founder & CEO)inMolly Shoichet(Co-Founder & Chief Science Officer)

Co-investorsStand Up VenturesToronto Innovation Acceleration Partners

Antios Therapeuticsantiostherapeutics.comin𝕏Nov 2021 Β· $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more

Antiva Biosciencesantivabio.cominApr 2023 Β· $53M

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in

Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersMPM BioImpactOUP (Osage University Partners)Sofinnova Ventures+3 more

Aurinia Pharmaceuticalsauriniapharma.comin𝕏Feb 2014

Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.

BiotechDigital HealthHealthtechMedical DevicesVictoria, US

Richard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)

BoardKurt von Emster(Director)in

Co-investorsNew Enterprise Associates (NEA)venBio Partners

Axonis Therapeuticsaxonis.usinOct 2024

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in

BoardCorey . Goodman(Director)inJonathan Leff(Director)in

Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+7 more

Bardybardydx.cominAcquired

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.

Digital HealthHealthtechMedical DevicesSeattle, US

Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)

Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesRC CapitalRex Health VenturesSV Health Investors+1 more

Brightangeltherapeuticsbrightangeltherapeutics.comin𝕏

Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections.

BiotechDeep TechToronto, CA

Leah Cowen(Co-founder & CSO)Luke Whitesell(Co-founder & Consultant)Dominic Jaikaran(President & CEO)in

Co-investorsToronto Innovation Acceleration Partners

Cardiac Dimensionscardiacdimensions.comin𝕏Mar 2025 Β· $53M

Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.

BiotechHealthtechMedical DevicesKirkland, US

Frederick A. Stewart(Executive Officer, Director)Rick Wypych(Executive Officer)in

BoardKurt Wheeler(Director)Nathan Every(Director)Douglas C. Fisher(Director)Gerry Brunk(Director)in

Co-investorsAPERTURE Venture PartnersRedbus VenturesAlly Bridge GroupClaret Capital PartnersJefferiesM.H. Carnegie & Co.

Congruencetxcongruencetx.comin

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

Clarissa Desjardins(Founder)in

Co-investorsOrbiMedAlexandriaDIMENSIONBDC Thrive Venture Fund for Women

Contralinecontraline.cominMay 2026

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

Kevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

Co-investorsBiotechnology Value FundMBX CapitalAllied Venture PartnersAmboy Street VenturesAurum Venture PartnersBeni Venture Capital+14 more

Corviamedicalcorviamedical.comin𝕏

Co-investorsAccelmed Partners

CV Therapeuticsgilead.comin𝕏

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin

Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalMenlo Ventures+5 more

Damonapharmadamonapharma.comin

Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Co-investorsAngelini VenturesNoeticToronto Innovation Acceleration Partners

Deka Biosciencesdekabiosciences.com

BiotechGermantown, US

John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)

BoardLu Han(Director)in

Co-investorsPlains VenturesEcho Investment CapitalLeaps by BayerMPM BioImpact

Endogenexendogenex.comin𝕏

Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.

Digital HealthHealthtechMedical DevicesMinneapolis, US

Stacey Pugh(Leadership (CEO))inChris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMelanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in

Co-investorsArboretum VenturesIntuitive VenturesLongitude Capital

enGeneengene.comin𝕏

enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.

BiotechMedical Devices

Co-investorsCTI Life Sciences Fund L.P.

Fusion Pharmaceuticalsfusionpharma.comin𝕏

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapSeroba Life SciencesVenture OntarioYsios CapitalAdams Street Partners+2 more

G1 Therapeuticsg1therapeutics.comFeb 2015

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

BiotechResearch Triangle Park, US

Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)

Co-investorsMountain Group CapitalRA CapitalSolasta VenturesHatteras Venture Partners

Guavatechnologiesguavatechnologies.comin𝕏acquired by Cytek Biosciences

BiotechDeep TechHealthtechMedical DevicesBellevue, US

Iteriontherapeuticsiteriontherapeutics.comin

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/Ξ²-catenin pathway.

BiotechHealthtech

Rahul Aras(Chief Executive Officer)inOvid Trifan(Chief Medical Officer)inSteve Horrigan(Chief Scientific Officer)in

Co-investorsGreen Park & Golf VenturesPortal Innovations

Kisojibiotechkisojibiotech.com

KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases.

AI & Machine LearningBiotechDeep Tech

Co-investorsRemiges Ventures, Inc.

Medexusmedexus.comin𝕏

Medexus Pharmaceuticals is a specialty pharmaceutical company focused on orphan drugs and rare disease treatments, with a portfolio of specialty and rare disease products.

BiotechHealthtechToronto, CA

Nervoniknervonik.cominApr 2026 Β· $52.5M

Nervonik develops peripheral nerve stimulation (PNS) systems designed for high-motion, dynamic activity, using a patented technology that adds biosensing and objective feedback to neuromodulation.

HardwareHealthtechMedical Devices

Co-investorsFoothill VenturesShangBay Capital LLCUS Venture PartnersAmzak Health

OncoMyx TherapeuticsinDec 2021

BiotechPhoenix, US

Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)

Co-investorsB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment PartnersLYZZ Capital+1 more

Opsensmedicalopsensmedical.comin𝕏

OpSens Medical develops sensor-guided medical devices, including fiber optic guidewires and hemodynamic monitoring systems, for use in interventional cardiology procedures.

Digital HealthMedical Devices

Read the Press Releasestryker.com

Stryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers.

Advanced ManufacturingHealthtechMedical Devices

Kevin Loboin

Co-investorsGefinor CapitalNew Enterprise Associates (NEA)Rex Health VenturesWindham Capital Partners

Sound Blade Medicalsoundblademedical.comJul 2026

SoundBlade Medical develops handheld histotripsy technology for non-invasive surgery, using focused ultrasound to treat tissue with precision.

HardwareHealthtechMedical Devices

Jeremy Brown(Co-Founder & CTO)inMatt Mallay(Co-Founder & Sr. Dir. R&D)inAndre Bezanson(Co-Founder & Dir. R&D)inEli Vlaisavljevich(Co-Founder)inRick Balys(Co-Founder)inNeil Barman(Chief Executive Officer)in

Co-investorsAmzak HealthAPERTURE Venture PartnersInvest Nova Scotia

Specificbiologicsspecificbiologics.comin

Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats.

BiotechDeep TechHealthtech

Spinal Kineticsspinalkinetics.comin

HealthtechSunnyvale, US

Thomas Afzal(Executive Officer, Director)

BoardPeter van der Velden(Director)inDavid Milne(Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)

Co-investorsHLM Venture PartnersSV Health InvestorsSV Life Sciences

Thinkresearchthinkresearch.com

Think Research works with health systems to improve care delivery through clinical software, clinical expertise, and hands-on operational support across access to care, clinical workflow, and medication safety.

Digital HealthHealthtechSaaS

Other

Tracked investments with no reachable website or further public details β€” typically companies that wound down, renamed, or were absorbed.

CeltaxsysCorvia MedicalMedexus PharmaceuticalsAssertiotxBauschEssapharmaForbiusGladius PharmaceuticalsKaipharmaceuticalsMorphotekResonantmedical

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.